Prevalence of resistance to colistin, tigecycline and minocycline in Acinetobacter baumannii isolated from clinical samples in 2014
Archives of Medical Laboratory Sciences,
Vol. 4 No. 3 (2018),
28 December 2019
https://doi.org/10.22037/amls.v4i3.22147
Abstract
Background: Colonization rate of Acinetobacter baumannii is increasing in hospitalized patients especially in long term hospitalized one and / or who were treat with extended spectrum antibiotics or anticancer. Antibiotic resistance in A. baumannii is considerable because more prevalence of them cause nosocomial infections and can impose high cost to health systems and patients. The aim of this study was determination of tigecycline, minocycline and colistin resistance A. baumannii in selected center in Tehran, Iran.
Materials and Methods: This study was descriptive and functional foundation. In this study A. baumannii were collected from Milad, Mofid, Taleghani, Motahari and Loghman hospital, Tehran and transferred to laboratory of pediatric infections research center. Collected bacteria were identified by conventional microbiology tests. Antibiotic susceptibility testing was determined according to CLSI guide line. Tigecycline, minocycline and colistin resistance strains were isolated.
Results: In this study, 105 A. baumannii were collected from five selected hospitals: 48 (46%) from Milad, 33 (31%) from Motahari, 17 (16%) from Loghman, 4 (4%) from Mofid and 3 (3%) from Taleghani hospital. The highest resistance was observed against cefepime and high frequency of carbapenem and minocycline was observed. On the other hand, observed resistance to aminoglycosides was 93% at least. Tigecycline is the most effective antibiotic after colistin. Colistin resistant confirmed just in one isolate by E. test.
Conclusion: The results of this study indicated that high rate of antibiotic resistance in A. baumannii even resistant to third and fourth generation of cephalosporin and carbapenem antibiotics. The treatment of MDR strains of A. baumannii become more complicated if the spread of them were not been controlled.
- Acinetobacter baumannii
- Antibiotic resistance
- Tigecycline
- Minocycline
How to Cite
References
Murray P, Baron E, Pfaller M, Tenover F, Yolken R. Manual of Clinical Microbiology. 7th, editor. Washington,D.C: ASM Press; 1999;P.517-525.
Bergogne-Bérézin E, Towner K. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. ClinMicrobiol Rev. Clin Microbiol Rev. 1996;9(2):148-65.
Szabó D, Szentandrássy J, Juhász Z, Katona K, Nagy K, Rókusz L. Imported PER-1 producing Pseudomonas aeruginosa, PER-1 producing Acinetobacter baumanii and VIM-2-producing Pseudomonas aeruginosa strains in Hungary. Ann Clin Microbiol Antimicrob. 2008;30;7:12.
Nazmul MHM, Jamal H, Fazlul MKK. Acinetobacter species-associated infections and their antibiotic susceptibility profiles in Malaysia. Biomed Res- India. 2012; 23 (4): 571-575
Neonakis IK, Spandidos DA, Petinaki E. Confronting multidrug-resistant Acinetobacter baumannii: a review. Int J Antimicrob Agents. 2011;37(2):102-9.
Maragakis LL, Perl TM. Acinetobacter baumannii Epidemiology, Antimicrobial Resistance and Treatment Options. Clin Infect Dis. 2008;15;46(8):1254-63.
Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother. 2012;67(7):1607-15.
Doi Y, Husain S, Potoski BA, McCurry KR, Paterson DL. Extensively drug-resistant Acinetobacter baumannii. Emerg Infect Dis. 2009;15(6):980-2.
Arroyo LA, Mateos I, González V, Aznar J. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Chemother. 2009;53(3):1295-6.
Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ, Cheong HJ.In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2007; 60(2):317-22.
Ozbek B, Sentürk A Postantibiotic effects of tigecycline, colistin sulfate, and levofloxacin alone or tigecycline-colistin sulfate and tigecycline-levofloxacin combinations against Acinetobacter baumannii Chemotherapy. 2010;56(6):466-71.
Azimi L, Motevallian A, EbrahimzadehNamvar A, Asghari B, Lari AR. Nosocomial infections in burned patients in motahari hospital, Tehran, Iran. Dermatol. Res. Pract. 2011:ID: 436952. doi:10.1155/2011/436952.
Alaghehbandan R, Azimi. L, RastegarLari A. Nosocomial infections among burn patients in Teheran, Iran: a decade later. Ann. Burns. Fire Disasters. 2012:25(1):3-7.
Owlia P, Azimi L, Gholami A, Asghari B, Lari AR. ESBL- and MBL-mediated resistance in Acinetobacter baumannii: a global threat to burnt patients. Infez Med. 2012:20(3):182-7.
Lari AR, Alaghehbandan. R. Nosocomial infections in an Iranian burn care center. Burns. 2000:26(8):737-40.
Voets GM, Fluit AC, Scharringa J, Stuart JC, Leverstein-van Hall MA. A set of multiplex PCRs for genitypic detection of extended-spectrum β-lactamases, carbapenemases, plasmid-,ediatedAmpC β-lactamases and OXA β-lactamaes. Int J Antimicrob Agents. 2011:37:356-359.
Ku WW, Kung CH, Lee CH, Tseng CP, Wu PF, Kuo SC, Chen TL, Lee YT, Wang FD, Fung CP. Evolution of carbapenem resistance in Acinetobacter baumannii: An 18-year longitudinal study from a medical center in northern Taiwan. J Microbiol Immunol Infect. 2015;48(1):57-64.
Ambretti S, Gaibani P, Berlingeri A, Cordovana M, Tamburini MV, Bua G, Paola Landini M, Sambri V. Evaluation of Phenotypic and Genotypic Approachesfor the Detection of Class A and Class B Carbapenemasesin Enterobacteriaceae. Microb Drug Resist. 2013:19(3):212-215.
Andriamanantena TS, Ratsima E, Rakotonirina HC, Randrianirina F, Ramparany L, Carod JF, Richard V, Talarmin A. Dissemination of multidrug resistant Acinetobacter baumannii in various hospitals of Antananarivo Madagascar.Ann. Clin Microbiol Antimicrob. 2010:30:9-17
Azimi L, Talebi M, Pourshafie MR, Owlia P, RastegarLari A.Characterization ofCarbapenemases in Extensively Drug Resistance Acinetobacter baumannii in a Burn Care Center in Iran. Int J Mol Cell Med. 2015;4(1):46-53.
RastegarLari A, Azimi L, Rahbar M, Fallah F, Alaghehbandan R. Phenotypic detection of Klebsiellapneumoniaecarbapenemase among burns patients: First report from Iran. Burns. 2013;39:174-176.
Robledo IE, Aquino EE, Vázquez GJ. Detection of the KPC gene in Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii during a PCR-based nosocomial surveillance study in Puerto Rico. Antimicrob Agents Chemother. 2011:55(6):2968-70.
Peymani A, Nahaei MR, Farajnia S, Hasani A, Mirsalehian A, Sohrabi N, Abbasi L. High prevalence of metallo-beta-lactamase-producing Acinetobacterbaumannii in a teaching hospital in Tabriz, Iran. Jpn J Infect Dis. 2011:64(1):69-71.
Soleymanzadeh-Moghadam S, Azimi L, Amani L, Rastegar Lari A, Alinejad F, Rastegar Lari A. Analysis of antibiotic consumption in burn patients.GMS Hyg Infect Control. 2015;9(10):1-5
http://city-life.blogsky.com/1390/11/30/post-28/
Gholami A, Barati M, Vahdani M, Vahdani H, Karimi M. Pattern of empirical antibiotic administration in emergency department of an educational hospital in Tehran. Razi J Med Sci. 2011;18(82/83):17–23.
Raveh D, Levy Y, Rudensky B, Yinnon AM. Longitudinal surveillance of antibiotic use in the hospital. QJ. Med. 2001:94: 141-51.
Liu BT, Song FJ, Zou M, Hao ZH, Shan H. Emergence of colistin resistance gene mcr-1 in Cronobactersakazakii producing NDM-9 and Escherichia coli from the same animal. Antimicrob Agents Chemother. 2017;24;61(2).
Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, Bassetti M, Malacarne P, Petrosillo N, Galdieri N, Mocavero P, Corcione A, Viscoli C, Zarrilli R, Gallo C, Utili R. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57(3):349-58.
Ricciardi R, Ricciardi AM, Danzi G In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii clinical isolates. . Infez Med. 2009; 17(4):236-9.
Bosó-Ribelles V, Romá-Sánchez E, Carmena J, Cáceres C, Bautista D.Tigecycline: a new treatment choice against Acinetobacter baumannii.Recent Pat Antiinfect Drug Discov. 2008; 3(2):117-22.
Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME.Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence.J AntimicrobChemother. 2008;62(1):45-55.
- Abstract Viewed: 368 times
- PDF Downloaded: 288 times